Companies
OPM Biosciences
custom OPM-CHO / OPM-293 media and feeds doubling antibody titre via high-throughput screening.
- Country
- China
cn
custom
cho
Coverage
| CN | EU | US | |
|---|---|---|---|
| cleanroom-facilities | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | CNY 354.91 million (FY 2025) | financialfilings.com · sg.finance.yahoo.com |
| Production site | Two cell culture media manufacturing sites in China | opmbio.com |
| Capacity | Liquid media capacity up to 2000 L/batch; dry powder up to 2000 kg/batch (Facility #2) | opmbio.com |
| Certification | ISO 9001:2015 certified; GMP compliant | opmbio.com |
| Regulatory approval | CSRC registration approval for asset restructuring (Dec 2025) and re-certified as High and New Technology Enterprise (Jan 2026) | law.asia |
Independent sources: financialfilings.com · law.asia · sg.finance.yahoo.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Media manufacturing (B2B production equipment) | cleanroom-facilities | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.